


JPMA's Visions

JPMA has formulated the JPMA's Vision for 2035, which depicts the ideal state a decade from now. This vision, grounded in the concept of Co-creation from a patient-centered perspective, serves as a compass for co-creating innovative new drugs and building a society where these drugs can be reliably delivered to patients who are waiting for them, together with patients, the public, and the government. To embody this vision, JPMA has also developed the JPMA's Policy Proposals for 2025, offering recommendations for a unified public-private industrial strategy.



JPMA's Vision for 2035



JPMA's Policy Proposals for 2025



(Available in Japanese only)

JPMA's Vision for 2035

Delivering Pharmaceutical Innovations Domestically and Globally

01



Consistently produce innovations to benefit health spans and the economy

- Pharmaceutical innovations
- Leading-edge scientific technology
- Pharmaceutical manufacturing technology
- Domestic manufacturing infrastructure
- Making Japan a science and technology powerhouse
- Fostering highly skilled talent
- PPI/E*
- Drug discovery that involves patients and the public
- Co-creation
- Drug discovery ecosystem
- Job creation
- Extending health spans
- Well-being
- Pharma as a core industry
- Economic growth

* Patient and Public Involvement/Engagement

02



Bring innovative new drugs to the public more quickly to enhance health security

- A social security system that gives patients swift access to "the latest treatments" and stable access to "global-standard treatments"
- Positive investment cycle
- Building an attractive domestic market
- Drug pricing that properly factors in the worth of innovation
- Health security for Japan

03



Commit to ethical conduct and transparency to foster trust in the pharma industry

- Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages)
- Overcome the social challenges raised by Japan's aging population
- Ethical soundness, code of behavior, and transparency
- Boost public literacy in health and medicine
- Social significance of pharmaceuticals and the pharma industry
- Encourage the public and younger people to enter the pharma industry
- Climate change
- Environmental issues

Patient and the public perspective

JPMA's Activities and Structure

Under the JPMA Board of Directors, 12 committees composed of member companies and 6 specialized organizations, including the Office of Pharmaceutical Industry Research (OPIR) which functions as a think tank, carry out a wide range of initiatives. These activities aim to establish a robust drug discovery ecosystem for the development of innovative pharmaceuticals, ensure compliance with regulatory frameworks such as the Pharmaceuticals and Medical Devices Act, and build trust with key stakeholders. Each committee and specialized body bring together a diverse pool of talent—from young professionals to experienced experts—working across

organizational boundaries. Through mutual collaboration and constructive exchange, they advance pharmaceutical innovation, promote the appropriate use of medicines, enhance transparency in distribution, foster international cooperation, and formulate policy proposals. In addition, JPMA conducts various surveys and research projects to address industry-wide challenges. By working closely with government authorities, patient advocacy groups, and other relevant organizations, JPMA supports the sound and sustainable development of the pharmaceutical industry.

Co-creation

To envision and shape the future of healthcare, JPMA co-creates value through collaboration both within and beyond the pharmaceutical industry. By engaging in simultaneous and multi-dimensional dialogue with a diverse range of stakeholders, and fostering mutual understanding across sectors, we aim to resolve common challenges and generate new value together.

▶ Please also see the message from JPMA President Miyabashira on the back.

Industrial Infrastructure

Through the activities of its committees and specialized organizations, JPMA develops the infrastructure (foundation) for the pharmaceutical industry to create innovative new drugs, including establishing a drug discovery ecosystem*, managing regulatory affairs such as the Pharmaceuticals and Medical Devices Act, and building trusting relationships with stakeholders.

*Drug Discovery Ecosystem: A collaborative framework where pharmaceutical companies, government agencies, universities, and other institutions work together to create innovative medicines.

Committees and Specialized Organizations


Thousands of professionals from member companies participate in JPMA's committees and specialized organizations. They actively engage in a wide range of themes based on business policies, plans, and implementation frameworks.

Committees

- Code Compliance Committee
- Pharmaceutical Industry Policy Committee
- Distribution Improvement Committee
- Drug Evaluation Committee
- Quality & Technology Committee
- Biopharmaceutical Committee

Specialized Organizations

- Regulatory Affairs Committee
- Intellectual Property Committee
- R&D Committee
- International Affairs Committee
- APAC Project
- Public Affairs Committee
- Consumer Consultation Review Committee
- Environmental Issue Committee



Member Companies (in alphabetical order)

As of January 1, 2026, JPMA is comprised of 68 research and development-based pharmaceutical companies.

- AbbVie GK
- KM Biologics Co.,Ltd.
- Alfresa Pharma Corporation
- Kowa Company, Ltd.
- Amgen K.K.
- ASAHI KASEI PHARMA CORPORATION
- ASKA Pharmaceutical Co.,Ltd.
- Astellas Pharma Inc.
- AstraZeneca K.K.
- BAYER YAKUHIN, LTD.
- Biogen Japan Ltd.
- Bristol-Myers Squibb K.K.
- CHUGAI PHARMACEUTICAL CO., LTD.
- DAIICHI SANKYO CO., LTD.
- EA Pharma Co., Ltd.
- Eisai Co., Ltd.
- ELI LILLY JAPAN K.K.
- Fuji Pharma Co., Ltd.
- FUJIFILM Toyama Chemical Co., Ltd.
- FUJIMOTO PHARMACEUTICAL CORP.
- FUSO PHARMACEUTICAL INDUSTRIES, LTD.
- GlaxoSmithKline K.K.
- Hisamitsu Pharmaceutical Co.,Inc
- JANSSEN PHARMACEUTICAL K.K.
- JCR Pharmaceuticals Co., Ltd.
- KAKEN PHARMACEUTICAL CO., LTD.
- KISSEI PHARMACEUTICAL CO., LTD.
- KM Biologics Co.,Ltd.
- SANTEN PHARMACEUTICAL CO., LTD.
- SANWA KAGAKU KENKYUSHO CO., LTD.
- SEIKAGAKU CORPORATION
- SENJU PHARMACEUTICAL CO., LTD.
- SHIONOGI & CO., LTD.
- Sumitomo Pharma CO., LTD.
- TAIHO PHARMACEUTICAL CO., LTD.
- MARUISHI PHARMACEUTICAL CO., LTD.
- Meiji Seika Pharma Co., Ltd.
- Merck Biopharma Co., Ltd.
- MOCHIDA PHARMACEUTICAL CO., LTD.
- MSD K.K.
- NIPPON BOEHRINGER INGELHEIM CO., LTD.
- NIPPON CHEMIPHAR CO., LTD.
- NIPPON KAYAKU CO., LTD.
- NIPPON SHINYAKU Co., Ltd.
- NIPPON ZOKI PHARMACEUTICAL CO., LTD.
- NOVARTIS PHARMA K.K.
- NOVO NORDISK PHARMA LTD.
- ONO PHARMACEUTICAL CO., LTD.
- OTSUKA PHARMACEUTICAL Co., Ltd.
- PFIZER JAPAN INC.
- Viatris Pharmaceuticals Japan G.K.
- WAKAMOTO PHARMACEUTICAL CO., LTD.
- ZERIA PHARMACEUTICAL CO., LTD.

Contributions and challenges in the pharmaceutical industry

Four Key Roles Played by the Pharmaceutical Industry

The pharmaceutical industry is expected to strive for (1) the realization of a society of health and longevity by creating innovative drugs, and (2) the contribution to economic growth in terms of stable tax-paying capacity as well as expansion of investment through assured earnings for the purpose of continuing and energizing R&D activities for new drugs. The pharmaceutical industry is also expected to contribute to (3) the development and spread of scientific technologies through

actions including taking up challenges in cutting-edge fields and promoting industry-academia-government collaboration in the process of vigorous R&D activities.

These contributions by the pharmaceutical industry are greatly anticipated to lead the growth and development of Japan as well as the world through (4) contributions to global health that include disseminating first-rate new drugs to the entire world and exhibiting leadership as one of the few countries developing new drugs.

JPMA Logo

Five Key Messages from the JPMA

1. Contribute to global healthcare through the development of new drugs
2. Drive the Japanese economy as a leading industry
3. Create innovative and highly effective pharmaceuticals
4. Represent companies with outstanding research and development capabilities
5. Promote patient-centered healthcare



Thoughts Behind the Logo

Symbolizing the five messages, the logo expresses the way we continue to move forward with the world. The five arcs encircling and rising from the central sphere express growth and aspiration, while the logo's blue tone evokes a sense of advancement, global outlook, technical excellence, and freshness.